Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82e0cdb7dcbb419d5983adf689720c17 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56977 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6881 |
filingDate |
2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7213f407b70cd3bf2fc6a8fa88df419f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72434f670a08dbf9b6fede22f57e30ee |
publicationDate |
2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11180547-B2 |
titleOfInvention |
Methods for reducing drug-induced liver injury |
abstract |
The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients. |
priorityDate |
2018-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |